“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502, our ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--True North Therapeutics, a clinical stage biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare ...
Dianthus Therapeutics' DNTH103, a selective C1s inhibitor, is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing profile. DNTH103's selective targeting minimizes ...
Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...
About ANX007 and Phase 2 ARCHER TrialANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback